Sagimet Biosciences Inc.
corporate_fare Company Profile
Sagimet Biosciences Inc. (NASDAQ:SGMT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for SGMT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for SGMT spans 10-Q, 8-K, 424B5, 4.
Recent high-impact activity:
- Sagimet Posts 31c Quarterly Loss as Phase 3 R&D Spending Jumps 68%
- Sagimet Q3 Loss Widens to $19.1M as AURORA Phase 3 Ramps; $275.8M Cash Plus $107.5M October Net
- Sagimet Shares Fall as $115M Offering Closes, Acne Drug Data Digested
- Sagimet Secures $107.5M in Underwritten Offering to Advance Phase 3 Acne Trial
- Sagimet Prices $115M Offering at $10.00 — Net Proceeds $107.5M to Fund Phase 3 Acne Trial
Financial Snapshot
Short Interest & Short Volume
10.47 days to coverFINRA reported short interest of 12,172,501 shares in SGMT as of the October 30, 2026 settlement, a 5.6% increase from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 43.0% of SGMT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for SGMT, detected from its recent SEC filings · based on capital-structure filings through 2026-09-30.
Offering Priced at $10.00 · Net Proceeds $107.5M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →